Document is current
Any future updates will be listed below
-
Authors
Franklin, Clio E. https://orcid.org/0009-0002-8187-756X
Achtyes, Eric
Altinay, Murat
Bailey, Kala
Bhati, Mahendra T.
Carr, Brent R.
Conroy, Susan K.
Husain, Mustafa M.
Khurshid, Khurshid A.
Lencz, Todd https://orcid.org/0000-0001-8586-338X
McDonald, William M.
Mickey, Brian J. https://orcid.org/0000-0002-7847-7680
Murrough, James https://orcid.org/0000-0001-6286-1242
Nestor, Sean https://orcid.org/0000-0002-8848-5027
Nickl-Jockschat, Thomas https://orcid.org/0000-0003-2616-6503
Nikayin, Sina https://orcid.org/0000-0001-9024-038X
Reeves, Kevin https://orcid.org/0000-0002-3799-119X
Reti, Irving M.
Selek, Salih
Sanacora, Gerard https://orcid.org/0000-0003-3722-8829
Trapp, Nicholas T.
Viswanath, Biju https://orcid.org/0000-0002-7317-1789
Wright, Jesse H.
Sullivan, Patrick https://orcid.org/0000-0002-6619-873X
Zandi, Peter P. https://orcid.org/0000-0001-8423-2623
Potash, James B. https://orcid.org/0000-0002-5802-8079
-
Funding
Funding for this research was provided by:
DBT India Alliance (IA/CPHI/20/1/505266)
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (R01MH121545, R01MH121542)
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health
- License Information
-
More Information
Article History
Received: 23 January 2024
Revised: 21 August 2024
Accepted: 27 August 2024
First Online: 15 October 2024
Competing interests
: PFS is a consultant and shareholder for Neumora Therapeutics. In the past 2 years GS has served as consultant to Abbvie, Ancora/Embark, Aptinyx, Atai, Axsome Therapeutics, Biogen, Biohaven Pharmaceuticals, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb, Clexio, Cowen, Denovo Biopharma, Daiichi Sankyo, ECR1, EMA Wellness, Freedom Biosciences, Gilgamesh, Intra-Cellular Therapies, Janssen, KOA Health, Levo therapeutics, Lundbeck, Merck, MiCure, Navitor Pharmaceuticals, Neurocrine, Novartis, Noven Pharmaceuticals, Perception Neuroscience, Praxis Therapeutics, Relmada Therapeutics, Sage Pharmaceuticals, Seelos Pharmaceuticals, Taisho Pharmaceuticals, Usona Insititute, Valeant, Vistagen Therapeutics, and XW Labs; and received research contracts from Johnson & Johnson/Janssen, Merck, and the Usona Institute over the past 36 months. Dr. Sanacora holds equity in Biohaven Pharmaceuticals, Freedom Biosciences, Gilead Relmada, and Tetricus and is a co-inventor on a US patent (#8,778,979) held by Yale University and a co-inventor on US Provisional Patent Application No. 047162-7177P1 (00754) filed on August 20, 2018, by Yale University Office of Cooperative Research. Yale University has a financial relationship with Janssen Pharmaceuticals and may receive financial benefits from this relationship. Dr. Sanacora does not receive any direct payments through this relationship and the University has put multiple measures in place to mitigate this institutional conflict of interest. Questions about the details of these measures should be directed to Yale University’s Conflict of Interest office. All other authors have no conflicting interests to declare.
